Although α7nAChR agonists reduced NF-κB transcriptional activity, IL-6 and TNF release, α7nAChR agonists worsened the effects of DSS-induced colitis or were ineffective in a model of TNBS-induced colitis (137). The gene discussed is NFKB1; the disease is colitis.